Basic Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4436-4455
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4436
Table 4 Relationship between BIRC3 and clinical pathology in human epidermal growth factor receptor 2 (-) group, n (%)

BIRClow group (n = 23)
BIRChigh group (n = 37)
P value
Sex (male)19 (82.6)24 (81.1)0.2701
Age (year)65.43 ± 10.7764.97 ± 7.580.1102
BMI (kg/m2)23.46 ± 3.4324.84 ± 3.770.8922
HER20.047
HER2 (-)16 (69.6) 16 (43.2)
HER2 (+)7 (30.4) 21 (56.8)
Tumor size (cm)3.43 ± 2.024.59 ± 1.840.5002
Differentiation0.489
Poor9 (39.1)24 (64.9)
Moderate14 (60.9)10 (27.0)
High0 (0.0)3 (8.1)
T stage0.001
15 (13.5)1 (2.7)
27 (18.9)6 (16.2)
310 (27.0)11 (29.7)
41 (2.7)19 (51.4)
N stage0.208
011 (29.7)8 (21.6)
110 (27.0)20 (54.1)
22 (5.4)5 (13.5)
30 (0.0)4 (10.8)
M stage0.691
023 (100.0)35 (94.6)
10 (0.0)2 (5.4)
TNM stage0.007
I4 (10.8)1 (2.7)
II5 (13.5)1 (2.7)
III12 (32.4)24 (64.9)
IV2 (5.4)11 (29.7)
OS (month)
mean ± SD32.2 ± 16.3321.81 ± 15.170.0152
Median (range) 33 (3-53) 15 (5-53) -
DFS (month)
mean ± SD26.74 ± 14.8018.57 ± 14.210.0402
Median (range) 26 (3-52) 15 (2-53) -